We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Bayer HealthCare Renews and Expands its License for Ariadne Pathway Studio and MedScan Technology

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Bayer HealthCare Renews and Expands its License for Ariadne Pathway Studio and MedScan Technology"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Ariadne has announced that Bayer HealthCare AG will renew and expand its license for Ariadne Pathway Studio software powered by MedScan Technology till the end of 2010 to use for pathway research, toxicology studies and microarray data analysis.

Pathway Studio is systems biology software for analysis of pathways, signaling networks, and microarray data interpretation. The underlying proprietary MedScan natural language processing technology provides an ability to extract pathway-related information from biomedical literature, including PubMed.

Bayer HealthCare will have more research sites working with Ariadne software, and an early access to MedScan extension for extracting toxicology data from text.

"Bayer HealthCare have used Pathway Studio for several years", said David Thorpe, Enterprise Sales Director at Ariadne. "MedScan allowed them to set up daily automated information extraction of PubMed, their journal subscriptions and text file archives, and to provide this information to researchers as a database of molecule regulation facts amenable for computational analysis".

"The availability of new tools like GSEA (Gene Set Enrichment Analysis) and databases on a centralized server is important for multi-faceted research teams at Bayer HealthCare", commented Ilya Mazo, President of Ariadne.

"To further advance our technology we have been developing MedScan Toxicology module that automatically compiles knowledge bases of small molecules, their influence on cell processes, interaction with proteins, and involvement in metabolic reactions and diseases. Bayer HealthCare is going to pioneer using this module in their research,” Mazo added.